Tanaka H
Graduate school of biomedical science Ph.D. program, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima Bunkyo-ku, Tokyo 113-8510, Japan.
Methods Inf Med. 2010;49(2):173-85. doi: 10.3414/ME9307. Epub 2010 Feb 22.
Recent important advances in the human genomics and post-genomic "omics" are now bringing about a new medical care which we call "omics-based medicine". In this article, we investigated the development and future possibilities of omics-based medicine.
We divided the development of omics-based medicine into three generations in order to clarify the main clinical goals and characteristics of informatics method of each generation, together with its future possibilities.
The first generation of omics-based medicine started with "genomic medicine" based on the inborn individual differences of genome. It has opened the study of genetic polymorphism of the diseases and promoted the personalized medication based on the pharmacogenetic/pharmacogenomic difference of the drug response. In the second generation of omics-based medicine, owing to the advances in the high-throughput technology, vast amount of the various post-genomic disease omics data containing comprehensive molecular information of diseased somatic cells has become available. It reflects the ongoing state of diseases more closely and enables the predictive medicine such as prognosis prediction of disease by applying the data-driven analysis. Finally, due to the rapidly growing knowledge about the cellular molecular network, system-level understanding of the disease, called systems pathology, becomes possible. It can fully exploit the substantial contents of disease omics and will lead to a comprehensive understanding of disease process by using model-driven analysis.
Omics-based medicine and systems pathology will realize a new personalized and predictive medicine.
人类基因组学和后基因组“组学”领域最近取得的重要进展正在带来一种我们称之为“基于组学的医学”的新型医疗模式。在本文中,我们研究了基于组学的医学的发展及其未来可能性。
为了阐明基于组学的医学各代的主要临床目标、信息学方法的特点及其未来可能性,我们将其发展分为三代。
第一代基于组学的医学始于基于基因组先天性个体差异的“基因组医学”。它开启了对疾病基因多态性的研究,并推动了基于药物反应的药物遗传学/药物基因组学差异的个性化用药。在第二代基于组学的医学中,由于高通量技术的进步,包含患病体细胞综合分子信息的大量各种后基因组疾病组学数据变得可用。它更紧密地反映了疾病的当前状态,并通过应用数据驱动分析实现了预测医学,如疾病预后预测。最后,由于对细胞分子网络的认识迅速增长,对疾病的系统层面理解,即系统病理学,成为可能。它可以充分利用疾病组学的大量内容,并通过使用模型驱动分析全面了解疾病过程。
基于组学的医学和系统病理学将实现一种新型的个性化和预测性医学。